Monday, May 6, 2013

Investopedia: Teva Still Too Cheap, But Still Too Uncertain

The story on the generics giant Teva Pharmaceutical (Nasdaq:TEVA) really hasn't changed all that much over the past year. For investors who can just buy, ignore the volatility, and maintain a long-term perspective, the shares look too cheap. On the other hand, the generic drug business has clearly lost momentum, and it's uncertain if “bio-similar” and a more focused approach to drug development will deliver the promised returns for this company. Consequently, value investors have a lot to like here, but they have to accept that the Street is probably not going to share that enthusiasm for some time yet.

Please continue here:

No comments: